Pantoprazole

Pantoprazole

SCHEMBL1994484

COc1ccnc(C[S+]([O-])c2nc3cc(OC(F)F)ccc3[nH]2)c1OC.[KH]

nearest known ligand 0.53

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ATP4A P20648 14/20 0.53
ATP4B P51164 14/20 0.53
CYP2C9 P11712 2/20 0.53
KDM4E B2RXH2 1/20 0.53
SLC22A2 O15244 1/20 0.53
DDAH1 O94760 1/20 0.53
ALDH1A1 P00352 1/20 0.53
LMNA P02545 1/20 0.53
ABCB1 P08183 1/20 0.53
CYP3A4 P08684 1/20 0.53
MAPT P10636 1/20 0.53
HPGD P15428 1/20 0.53
ALOX15 P16050 1/20 0.53
ADRA1A P35348 1/20 0.53
FASN P49327 1/20 0.53
SLC47A2 Q86VL8 1/20 0.53
SLC47A1 Q96FL8 1/20 0.53
ABCG2 Q9UNQ0 1/20 0.53
ATP1A1 P05023 7/20 0.45
ATP1B1 P05026 7/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Pantoprazole SCHEMBL4192305 0.99 ATP4A (0.54) ATP4AATP4BCYP2C9KDM4ESLC22A2
Pantoprazole SCHEMBL29465 0.99 ATP4A (0.54) ATP4AATP4BCYP2C9KDM4ESLC22A2
Pantoprazole SCHEMBL6469440 0.99 ATP4A (0.54) ATP4AATP4BCYP2C9KDM4ESLC22A2
Pantoprazole SCHEMBL29425016 0.99 ATP4A (0.54) ATP4AATP4BCYP2C9KDM4ESLC22A2
Pantoprazole SCHEMBL4942069 0.99 ATP4A (0.54) ATP4AATP4BCYP2C9KDM4ESLC22A2
Pantoprazole SCHEMBL12662938 0.99 ATP4A (0.54) ATP4AATP4BCYP2C9KDM4ESLC22A2
Pantoprazole SCHEMBL3716300 0.98 ATP4A (0.53) ATP4AATP4BCYP2C9KDM4ESLC22A2
Pantoprazole SCHEMBL4320242 0.98 ATP4A (0.53) ATP4AATP4BCYP2C9KDM4ESLC22A2
Pantoprazole SCHEMBL6262319 0.98 ATP4A (0.53) ATP4AATP4BCYP2C9KDM4ESLC22A2
Pantoprazole SCHEMBL3542 0.98 ATP4A (0.53) ATP4AATP4BCYP2C9KDM4ESLC22A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-102718751-B Pantoprazole salt crystal form and preparation method thereof Hangzhou zhongmei huadong pharmaceutical co ltd 2014-02-19 CN claimed
CN-102718751-A Pantoprazole salt crystal form and preparation method thereof Hangzhou zhongmei huadong pharmaceutical co ltd 2012-10-10 CN claimed
CN-1369491-A Chiral pantorazole salt and its preparing process UNIV SHENYANG PHARMACY (CN) 2002-09-18 CN claimed
CN-113425717-B Medicament for improving efficacy of oral helicobacter pylori vaccine and application thereof 成都欧林生物科技股份有限公司 2023-06-16 CN disclosed
CN-113425717-A Medicament for improving efficacy of oral helicobacter pylori vaccine and application thereof 成都欧林生物科技股份有限公司 2021-09-24 CN disclosed
CN-104803983-B A kind of compound of pantoprazole sodium and preparation thereof 山东罗欣药业集团股份有限公司 2016-09-28 CN disclosed
CN-105213390-A A kind of medicine pantoprazole composition of sodium for the treatment of peptic ulcer YANG XIANMEI 2016-01-06 CN disclosed
CN-105147616-A Medicine namely pantoprazole sodium composition dry suspension for treating gastric ulcer QINGDAO LANSHENGYANG PHARMACEUTICAL BIOTECHNOLOGY CO LTD 2015-12-16 CN disclosed
CN-105106204-A Medicinal pantoprazole sodium composition for treating digestive system diseases QINGDAO HUAZHICAO MEDICAL TECHNOLOGY CO LTD 2015-12-02 CN disclosed
CN-105078981-A Freeze-dried powder injection of pantoprazole sodium composition for treating stomach illness QINGDAO HUAZHICAO PHARMACEUTICAL TECHNOLOGY CO LTD 2015-11-25 CN disclosed
CN-105055411-A Pantoprazole sodium composition for treating gastric ulcer QINGDAO HUAZHICAO PHARMACEUTICAL CO LTD 2015-11-18 CN disclosed
CN-101961334-A Combined drug of pantoprazole and domperidone Chengdu zihao pharmaceutical co ltd 2011-02-02 CN disclosed
CN-1835738-A Pharmaceutical compositions having a swellable coating REDDYS LAB INC DR (US) 2006-09-20 CN disclosed
EP-1681052-A1 Solid pharmaceutical dosage forms for reducing the bioavailability food effect Dr. Reddy's Laboratories Ltd. (IN) 2006-07-19 EP disclosed
EP-1601667-A2 CRYSTALLINE AND AMORPHOUS SOLIDS OF PANTOPRAZOLE AND PROCESSES FOR THEIR PREPARATION Teva Pharmaceutical Industries Limited (IL) 2005-12-07 EP disclosed
US-20050147663-A1 Method of treatment for improved bioavailability DR. REDDY'S LABORATORIES, INC. 2005-07-07 US disclosed
US-20050042277-A1 Pharmaceutical compositions having a swellable coating DR. REDDY'S LABORATORIES, INC. 2005-02-24 US disclosed
US-20040235904-A1 Crystalline and amorphous solids of pantoprazole and processes for their preparation TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) 2004-11-25 US disclosed
WO-2004080961-A2 CRYSTALLINE AND AMORPHOUS SOLIDS OF PANTOPRAZOLE AND PROCESSES FOR THEIR PREPARATION TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) 2004-09-23 WO disclosed
CN-1369491-A Chiral pantorazole salt and its preparing process UNIV SHENYANG PHARMACY (CN) 2002-09-18 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040235904-A1 Crystalline and amorphous solids of pantoprazole and processes for their preparation CYP3A4, CYP2C19, CYP4B1 ATP4A 245/4885ATP4B 156/4885CYP2C9 13/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.